Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Recce Pharmaceuticals Ltd. ( (AU:RCE) ) just unveiled an update.
Recce Pharmaceuticals Ltd has announced the final notification of its selective buy-back of performance shares, totaling 8,754,423 securities at a consideration of AUD 87.54. This strategic move is likely to impact the company’s financial structure and could influence its market positioning by potentially increasing shareholder value.
The most recent analyst rating on (AU:RCE) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Recce Pharmaceuticals Ltd. stock, see the AU:RCE Stock Forecast page.
More about Recce Pharmaceuticals Ltd.
Recce Pharmaceuticals Ltd is a company operating in the pharmaceutical industry, focusing on the development and commercialization of synthetic anti-infectives designed to address the growing threat of antibiotic-resistant superbugs.
Average Trading Volume: 113,112
Technical Sentiment Signal: Hold
Current Market Cap: A$127.2M
Learn more about RCE stock on TipRanks’ Stock Analysis page.